Tratamiento de cáncer de pulmón metastásico (estadio IV) : segundo consenso de expertos, Asociación Colombiana de Hematología y Oncología (ACHO), 2019.

Treatment of metastatic lung cancer (stage IV) : second expert consensus, Colombian Association of Hematology Oncology (ACHO), 2019.

Contenido principal del artículo

Aylen Vanessa Ospina
Ricardo Brugés
Mauricio Lema
Gilberto de Lima Lopes Jr.
Mariano Provencio
Rodolfo Gómez
Milton Lombana
José Lobatón
Andrés Yepes
Diego Gómez Abreo
Ricardo Duarte
Carlos Vargas
Luis Pino
Jaime González
Jesús Insuasty
Ray Manneh Kopp
Pedro Ramos
Javier Godoy
Álvaro Gómez
Carlos Alberto Castro

Resumen

Introducción: el cáncer de pulmón representa una de las patologías oncológicas más frecuentes, con una incidencia del 11,6% y una mortalidad del 18,4%1,2. Durante los últimos años han surgido nuevas tecnologías en el tratamiento de este tipo de cáncer que han impactado positivamente la supervivencia de los pacientes3 . Como alternativa a una guía de práctica clínica, los consensos de expertos son una herramienta para generar documentos a fin de orientar y unificar la práctica médica. Métodos: se llevó a cabo el segundo consenso formal de expertos constituido por 17 oncólogos de la Asociación Colombiana de Hematología y Oncología de las principales ciudades e instituciones del país. Se realizó en cuatro momentos: donde se calificaron preguntas estructuradas por el grupo desarrollador que al final fueron consensuadas en una reunión presencial (nominal). Resultados: se construyeron y calificaron 35 preguntas sobre el tratamiento del cáncer de pulmón metastásico (estadio IV), con sus respectivas sugerencias basadas en la experticia y evidencia disponible reconocidas nacional e internacionalmente, teniendo en cuenta el contexto y regulación del sistema de salud colombiano.

Detalles del artículo

Biografía del autor/a (VER)

Aylen Vanessa Ospina, Universidad de los Andes

Médica, oncóloga clínica. ICCAL Hospital Universitario Fundación Santa Fe de Bogotá. Profesora clínica, Universidad de los Andes (Bogotá).

Ricardo Brugés, Pontificia Universidad Javeriana

Médico, oncólogo clínico. Instituto Nacional de Cancerología - Hospital Universitario San Ignacio. Profesor asociado de Medicina Interna, Pontificia Universidad Javeriana (Bogotá).

Mauricio Lema, Clínica de Oncología Astorga

Médico, hematooncólogo. Clínica de Oncología Astorga (Medellín).

Gilberto de Lima Lopes Jr., University of Miami

MD, MBA, FAMS, director médico de programas internacionales y director asociado oncología global. Sylvester Comprehensive Cancer Center, University of Miami.

Mariano Provencio, Universidad Autónoma de Madrid

MD, oncólogo médico. Jefe del Departamento de Oncología Médica, Hospital Universitario Puerta de Hierro - Universidad Autónoma de Madrid. Presidente del Grupo Español de Cáncer de Pulmón (GEP).

Rodolfo Gómez, IDC Las Américas

Médico, oncólogo clínico. IDC Las Américas (Medellín).

Milton Lombana, Clínica de Occidente

Médico, hematooncólogo. Clínica de Occidente (Cali).

José Lobatón, IMAT Oncomédica

Médico, hematooncólogo. IMAT Oncomédica (Montería).

Andrés Yepes, Clínica Vida Fundación

Médico, oncólogo clínico. Clínica Vida Fundación (Medellín).

Diego Gómez Abreo, Hospital Internacional de Colombia

Médico, oncólogo clínico. Instituto de Cáncer, Hospital Internacional de Colombia (Bucaramanga).

Ricardo Duarte, Clínica Reina Sofía

Médico, oncólogo clínico. Clínica Reina Sofía - Colsanitas (Bogotá).

Carlos Vargas, Clínica El Country

Médico, oncólogo clínico. Clínica El Country (Bogotá).

Luis Pino, Hospital Universitario Fundación Santa Fe de Bogotá

Médico, hematooncólogo. Hospital Militar Central, Hospital Universitario Fundación Santa Fe de Bogotá (Bogotá).

Jaime González, Oncólogos de Occidente

Médico, hematooncólogo. Oncólogos de Occidente (Manizales, Armenia, Pereira).

Jesús Insuasty, Hospital Universitario de Santander

Médico, oncólogo clínico. Profesor del Departamento de Medicina Interna, Universidad Industrial de Santander, Hospital Universitario de Santander (Bucaramanga).

Ray Manneh Kopp, Clínica Porto Azul

Médico, oncólogo clínico. Sociedad de Hematología y Oncología del Cesar - Clínica Porto Azul (Valledupar, Barranquilla).

Pedro Ramos, Sanitas EPS

Médico, oncólogo clínico. Oncocare - Sanitas EPS (Bogotá).

Javier Godoy, Clínica de Marly

Médico, hematooncólogo. Clínica de Marly (Bogotá).

Álvaro Gómez, Instituto de Oncología

Médico, hematooncólogo. Hematooncólogos - Instituto de Oncología (Cali).

Carlos Alberto Castro, Fundación Universitaria de Ciencias de la Salud

Médico, epidemiólogo. SIIES Consultores, Investigación y Educación en Salud. Profesor asistente, Fundación Universitaria de Ciencias de la Salud (Bogotá).

Referencias (VER)

Arrieta O, Guzmán-de Alba E, López LF, Acosta-Espinoza A, Latorre-Alexander J, Meza JF, et al. Consenso nacional de diagnóstico y tratamiento del cáncer de pulmón de células no pequeñas. Revista de Investigación Clínica. 2013;5(S1):5-84.

UICC. New Global Cancer Data: Globocan 2018 [internet]. EE. UU.; 2018. Disponible en: https://www.uicc.org/news/new-global-cancer-data-globocan-2018

Gettinger S. Immunotherapy of advanced non-small cell lung cancer with immune checkpoint inhibition. EE. UU.: UpToDay; 2018.

Ospina AV, Brugés R, Lema M, De Lima Lopes Jr. G, Gómez, G, et al. Tratamiento de cáncer de pulmón metastásico (estadio IV) de célula no pequeña. Consenso de expertos, Asociación Colombiana de Hematología y Oncología (ACHO). Rev Col Hem Onc. 2018;5(1):61-71.

American Cancer Society (ACS). Cáncer de pulmón de células no pequeñas: estadísticas [internet]. EE. UU.: Cancer. net; 2017. Disponible en: https://www.cancer.net/es/tiposde-c%C3%A1ncer/c%C3%A1ncer-de-pulm%C3%B3nc%C3%A9lulas-no-peque%C3%B1as/estad%C3%ADsticas.

World Health Organization. Cancer today, incidence and mortality of lung cancer [internet]. WHO; 2019. Disponible en: https://gco.iarc.fr/today/online-analysis-multi-bars

Colombia, Ministerio de Salud y Protección Social. Guía de práctica clínica para la detección temprana, diagnóstico, estadificación y tratamiento del cáncer de pulmón. Guía para profesionales de la salud [internet]. Colombia; 2014. Disponible en: http://gpc.minsalud.gov.co/gpc_sites/repositorio/forms/allitems.aspx?rootfolder=/gpc_sites/repositorio/conv_563/gpc_c_pulmon&folderctid=0x012000f43cfde8d8154047b4b4b9b88e72b8b7&view=%7Bc81f0233-558c-49af-a456-55fa1462ce27%7D

Instituto Nacional de Cancerología (INC). Análisis de situación del cáncer en colombia 2015 [internet]. Colombia; 2015. Disponible en: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0ahUKEwiV96a48fXbAhWOv1MKHSb-DIYQFggnMAA&url=http%3A%2F%2F https://www.cancer.gov.co%2FSituacion_del_Cancer_en_Colombia_2015.pdf&usg=AOvVaw17RZT_CxhHpz3dbWC_tzQ6

CDAC-FCDEDA. Indicadores de gestión del riesgo en pacientes con cáncer de pulmón [internet]. Colombia; 2018. Disponible en: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=21&ved=0ahUKEwibu-bIgO3aAhWC7FMKHSsDA9U4ChAWCFcwCg&url=https%3A%2F%2Fcuentadealtocosto.org%2Fsite%2Fimages%2FIndicadores_de_gestion_del_riesgo_en_pacientes_con_Cancer_de_Pulmon.pdf&usg=AOvVaw38adFfKnJX8glkn-GmDcnm

Asua Batarrita J. Entre el consenso y la evidencia científica. Gaceta Sanitaria. 2005;19:65-70.

Alva Díaz C, García-Mostajo JA, Gil-Olivares F, Timana R, Pimentel P, Canelo-Aybar C. Guías de práctica clínica: evolución, metodología de elaboración y definiciones actuales. Acta Médica Peruana. 2017;34:317-22.

Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (Keynote-010): a randomised controlled trial. Lancet. 2016;387(10027):1540-50.

Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016;387(10026):1415-26.

Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba, II, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA.2014;311(19):1998-2006.

Leighl NB, Rekhtman N, Biermann WA, Huang J, Mino-Kenudson M, Ramalingam SS, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. J Clin Oncol. 2014;32 (32):3673-9.

Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 2013;137 (6):828-60.

Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30(8):863-70.

Sacher AG, Paweletz C, Dahlberg SE, Alden RS, O’Connell A, Feeney N, et al. Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol. 2016;2(8):1014-22.

Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018;142 (3):321-46.

Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013;8(7):823-59.

Wu YL, Sequist LV, Hu CP, Feng J, Lu S, Huang Y, et al. EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. Br J Cancer. 2017;116(2):175-85.

Gridelli C, Ciardiello F, Gallo C, Feld R, Butts C, Gebbia V, et al. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol. 2012;30(24):3002-11.

Brugger W, Triller N, Blasinska-Morawiec M, Curescu S, Sakalauskas R, Manikhas GM, et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced nonsmall-cell lung cancer. J Clin Oncol. 2011;29(31):4113-20.

Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhász E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebocontrolled phase 3 study. Lancet Oncol. 2010;11 (6):521-9.

Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (Optimal, CTONG-0802). Ann Oncol. 2015;26(9):1877-83.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as firstline treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (Eurtac): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239-46.

Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, Ensure study. Ann Oncol. 2015;26 (9):1883-9.

Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361 (10):947-57.

Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, firstline study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29 (21):2866-74.

Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11 (2):121-8.

Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013;24(1):54-9.

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362 (25):2380-8.

Oizumi S, Kobayashi K, Inoue A, Maemondo M, Sugawara S, Yoshizawa H, et al. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. Oncologist. 2012;17(6):863-70.

Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012;13(5):528-38.

Wu YL, Zhou C, Hu C-P, Feng JF, Lu S, Huang Y, et al. LUXLung 6: a randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for

Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. J Clin Oncol. 2013;31(15 suppl):8016.

Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327-34.

Yang JC, Hirsh V, Schuler M, Yamamoto N, O’Byrne KJ, Mok TS, et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3342-50.

Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A, et al. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol. 2013;31(27):3335-41.

Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213-22.

FDA. Approved Drug Products, june 2018 [internet]. EE. UU.; 2018. Disponible en: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=reportsSearch.process

Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, et al. Alectinib versus crizotinib in patients with ALK-positive nonsmall-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017;390 (10089):29-39.

Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim D-W, et al. Alectinib versus crizotinib in untreated ALK-positive nonsmall-cell lung cancer. N Engl J Med. 2017;377 (9):829-38.

Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371 (23):2167-77.

Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (Ascend-4): a randomised, open-label, phase 3 study. Lancet. 2017;389 (10072):917-29.

Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, et al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX Study. J Thorac Oncol. 2019;14(7):1233-43.

Zhou Y, Lu S, Kim T, Reungwetwattana J, Zhou Y, Zhang J, et al. Primary results of Alesia: a randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatmentnaïve ALK+ advance [internet]. Alemania: ESMO 2018 Congress; 2018. Disponible en: https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Primary-results-ofALESIA-A-randomised-phase-III-open-label-study-of-alectinibvs-crizotinib-in-Asian-patients-with-treatment-naive-ALK-advanced-NSCLC

Ou SH, Janne PA, Bartlett CH, Tang Y, Kim DW, Otterson GA, et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol. 2014;25 (2):415-22.

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFRmutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378 (2):113-25.

Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, et al. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J Clin Oncol. 2018;36 (22):2244-50.

Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Mahajan A, et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J Clin Oncol. 2019:Jco1901154.

Iuchi T, Shingyoji M, Sakaida T, Hatano K, Nagano O, Itakura M, et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer. 2013;82 (2):282-7.

Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, Holodny AI, et al. “Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol. 2011;13 (12):1364-9.

Gerber NK, Yamada Y, Rimner A, Shi W, Riely GJ, Beal K, et al. Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma. Int J Radiat Oncol Biol Phys. 2014;89 (2):322-9.

Magnuson WJ, Yeung JT, Guillod PD, Gettinger SN, Yu JB, Chiang VL. Impact of deferring radiation therapy in patients with epidermal growth factor receptor-mutant non-small cell lung cancer who develop brain metastases. Int J Radiat Oncol Biol Phys. 2016;95 (2):673-9.

Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. 2018:Jco2018783118.

Nishie K, Kawaguchi T, Tamiya A, Mimori T, Takeuchi N, Matsuda Y, et al. Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations. J Thorac Oncol. 2012;7 (11):1722-7.

Janne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372 (18):1689-99.

Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (Impress): a phase 3 randomised trial. Lancet Oncol. 2015;16(8):990-8.

Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, et al. Osimertinib in pretreated T790M-positive advanced nonsmall-cell lung cancer: AURA study phase II extension component. J Clin Oncol. 2017;35(12):1288-96.

Riely GJ, Kris MG, Zhao B, Akhurst T, Milton DT, Moore E, et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res. 2007;13(17):5150-5.

NCCNN-CPGI. Non-small cell lung cancer [internet]. EE. UU.; 2019. Disponible en: https://www.nccn.org/professionals/physician_gls/default.aspx

Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378 (24):2288-301.

Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363 (9422):1665-72.

Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys. 1999;45 (2):427-34.

Zhou L, He J, Xiong W, Liu Y, Xiang J, Yu Q, et al. Impact of whole brain radiation therapy on CSF penetration ability of icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: results of phase I dose-escalation study. Lung Cancer. 2016;96:93-100.

Zeng YD, Liao H, Qin T, Zhang L, Wei WD, Liang JZ, et al. Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy. Oncotarget.2015;6(10):8366-76.

Deng Y, Feng W, Wu J, Chen Z, Tang Y, Zhang H, et al. The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer. Mol Clin Oncol. 2014;2(1):116-20.

Togashi Y, Masago K, Fukudo M, Terada T, Fujita S, Irisa K, et al. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol. 2010;5(7):950-5.

Tamiya A, Tamiya M, Nishihara T, Shiroyama T, Nakao K, Tsuji T, et al. 1241P - Afatinib efficacy and cerebrospinal fluid concentration in NSCLC patients with EGFR mutation developing leptomeningeal carcinomatosis. ESMO 2016 Congress 2016. Disponible en: http://oncologypro.esmo.org/Meeting-Resources/ESMO-2016/Afatinib-efficacy-and-cerebrospinal-fluid-concentration-in-NSCLC-patients-with-EGFR-mutation-developingleptomeningeal-carcinomatosis

Ballard P, Yates JW, Yang Z, Kim DW, Yang JC, Cantarini M, et al. Preclinical comparison of osimertinib with other EGFRTKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22 (20):5130-40.

Wu YL, Zhou C, Hu CH, Feng JF, Lu S, Huang Y, et al. LUXLung 6: a randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. J Clin Onc. 2013;31 (15suppl):8016.

Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963-71.

Wu YL, Yang JC, Kim DW, Lu S, Zhou J, Seto T, et al. Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancer. J Clin Oncol. 2018;36(14):1405-11.

Lim SM, Kim HR, Lee JS, Lee KH, Lee YG, Min YJ, et al. Openlabel, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement. J Clin Oncol. 2017;35(23):2613-8.

Drilon A, Somwar R, Wagner JP, Vellore NA, Eide CA, Zabriskie MS, et al. A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer. Clin Cancer Res. 2016;22(10):2351-8.

Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-28.

Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: Avaperl (MO22089). J Clin Oncol. 2013;31(24):3004-11.

Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland A, et al. Dabrafenib plus trametinib in patients with pre viously untreated BRAF (V600E)-mutant metastatic non-smallcell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18 (10):1307-16.

Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik CS, et al. Dabrafenib plus trametinib in patients with previously treated BRAF (V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016;17 (7):984-93.

Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med. 2015;372 (21):2018-28.

Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med. 2018;378(0):2078-92.

Cappuzzo F, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. LBA53IMpower130: progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. Ann Oncol. 2018;29 (suppl 8).

Barlesi F, Nishio M, Cobo M, Steele N, Paramonov, V, et al. A study of atezolizumab in combination with carboplatin or cisplatin + pemetrexed compared with carboplatin or cisplatin + pemetrexed in participants who are chemotherapy-naive and have stage IV non-squamous non-small cell lung cancer (NSCLC) (IMpower 132) [internet]. Alemania: ESMO 2018; 2018. Disponible en: https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/IMpower132-efficacy-of-atezolizumabatezo-carboplatin-carbo-cisplatin-cis-pemetrexed-pem-as-1Ltreatment-in-key-subgroups-with-stage-IV-non-squamousnon-small-cell-lung-cancer-NSCLC.

Lopes G, Wu Y-L, Kudaba I, Kowalski D, Cho BC, Castro G, et al. Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥1%: openlabel, phase 3 Keynote-042 study. J Clin Oncol. 2018;36 (18 suppl):LBA4-LBA.

Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823-33.

Zhou Y, Lin Z, Zhang X, Chen C, Zhao H, Hong S, et al. First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy. J Immunother Cancer. 2019;7:120.

Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA. 2004;292(4):470-84.

Perol M, Chouaid C, Perol D, Barlesi F, Gervais R, Westeel V, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2012;30(28):3516-24.

Rodriguez P, Neninger E, García B, Popa X, Viada C, Luaces P, et al. Safety, immunogenicity and preliminary efficacy of multiplesite vaccination with an epidermal growth factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients. Journal of Immune Based Therapies and Vaccines. 2011;9(1):7.

Rodriguez PC, Popa X, Martinez O, Mendoza S, Santiesteban E, Crespo T, et al. A phase III clinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res. 2016;22(15):3782-90.

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255-65.

Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35 (35):3924-33.

Castro C, Cardona AF, Revéiz L, Serrano SJ, Carranza H, Vargas CA, et al. Cáncer de pulmón de célula no pequeña metastásico. Tratamiento actual basado en la evidencia* (ONCOLGroup). Acta Médica Colombiana. 2010;35:53-81.

Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373 (2):123-35.

Peters S, Gettinger S, Johnson ML, Janne PA, Garassino MC, Christoph D, et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed deathligand 1-selected advanced non-small-cell lung cancer (BIRCH). J Clin Oncol. 2017;35 (24):2781-9.

Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15(2):143-55.

Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18 (10):2095-103.

Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22 (9):1589-97.

Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B, Nicholson M, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer-a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-small cell lung cancer. Br J Cancer.2000;83 (4):447-53.

Cortot AB, Audigier-Valette C, Molinier O, Moulec SL, Barlesi F, Zalcman G, et al. Weekly paclitaxel plus bevacizumab versus docetaxel as second or third-line treatment in advanced nonsquamous non-small cell lung cancer (NSCLC): Results from the phase III study IFCT-1103 Ultimate. J Clin Oncol. 2016;34 (15 suppl):9005.

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. Pembrolizumab plus chemotherapy for squamous nonsmall-cell lung cancer. N Engl J Med. 2018;379(21):2040-51.

Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (Keynote-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393 (10183):1819-30.

Fidias PM, Dakhil SR, Lyss AP, Loesch DM, Waterhouse DM, Bromund JL, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2009;27(4):591-8.

Castro C, Cardona AF, Revéiz L, Serrano SJ, Carranza H, Vargas CA, et al. Cáncer de pulmón de célula no pequeña metastásico. Tratamiento actual basado en la evidencia* (ONCOLGroup). Acta Médica Colombiana. 2010;35:53-81.

Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, et al. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol. 2018;4(11):1543-52.

Spigel DR, McLeod M, Hussein MA, Waterhouse DM, Einhorn L, Horn L, et al. 1297O Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced nonsmall cell lung cancer (NSCLC). Ann Oncol. 2017;28 (suppl 5).

Horn L, Mansfield AS, Szcz sna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379 (23):2220-9.

American Cancer Society. Medicamentos de terapia dirigida para el cáncer de pulmón no microcítico [internet]. EE.UU.; 2017 Disponible en: https://www.cancer.org/es/cancer/cancerde-pulmon-no-microcitico/tratamiento/terapias-dirigidas.html

NCBI. ROS1 ROS proto-oncogene 1, receptor tyrosine kinase [Homosapiens (human)] [internet]. EE. UU.; 2018. Disponible en: https://www.ncbi.nlm.nih.gov/gene/6098

NCBI. Programmed cell death 1 ligand 1 [internet]. EE. UU.; 2017. Disponible en: https://www.ncbi.nlm.nih.gov/gene/100196322

GHR-NLM. B-Raf proto-oncogene, serine/threonine kinase [internet]. EE. UU.; 2017. Disponible en: https://ghr.nlm.nih.gov/gene/BRAF

ECOG. ECOG performance status [internet]. EE. UU.; 2018. Disponible en: http://ecog-acrin.org/resources/ecog-performancestatus